Enantiomer–enantiomer interaction of ifosfamide in the rat

References

• Bode W, Toet AE, Stolker AA, Van Ginkel LA, Groen K, Wemer J, De Wilt DJ. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat. Chirality 1995; 7: 626–631
   PubMedGoogle Scholar
• Carr RA, Pasutto FM, Foster RT. Stereospecific evaluation of sotalol pharmacokinetics in rat model: Evidence suggesting an enantiomeric interaction. Biopharmacology and Drug Disposition 1994; 15: 109–120
   PubMedGoogle Scholar
• Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 1993; 53: 5629–5637
   PubMed Web of Science ®Google Scholar
• Desta Z, Soukhova N, Morocho AM, Flackhart DA. Stereoselective metabolism of cisapride and enantiomer–enantiomer interaction in human cytochrome P450 enzymes: Major role of CYP3A. Journal of Pharmacology and Experimental Therapy 2001; 298: 508–520
   PubMed Web of Science ®Google Scholar
• Farmer PB. Enantiomers of cyclophosphamide and iphosphamide. Biochemistry and Pharmacology 1988; 37: 145–148
   PubMed Web of Science ®Google Scholar
• Gibaldi M. Stereoselective and isozyme-selective drug interactions. Chirality 1993; 5: 407–413
   PubMed Web of Science ®Google Scholar
• Goren MP, Wright RK, Pratt CB, Pell PE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; ii: 1219–1220
   Google Scholar
• Granvil CP, Ducharme J, Leyland-Joes B, Trudeau M, Wainer IW. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemotherapy and Pharmacology 1996; 37: 451–456
   PubMed Web of Science ®Google Scholar
• Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metabolism and Disposition 1999; 27: 533–541
   PubMed Web of Science ®Google Scholar
• Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: Therapeutic pitfalls. Journal of Pharmacology Science 1989; 78: 695–715
   PubMed Web of Science ®Google Scholar
• Lee EJD, Williams KM. Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacokinetics 1990; 18: 339–345
   PubMed Web of Science ®Google Scholar
• Li G, Gong PL, Qiu J, Zeng FD, Klotz U. Stereoselective steady-state disposition and action of propafenone in Chinese subjects. British Journal of Clinical Pharmacology 1998; 46: 441–445
   PubMed Web of Science ®Google Scholar
• Lu H, Wang JJ, Chan KK, Young D. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats. Drug Metabolism and Disposition 1998; 26: 476–482
   PubMed Web of Science ®Google Scholar
• Robinson MA, Mehvar R. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: The role of plasma protein binding. Biopharmacology and Drug Disposition 1996; 17: 577–587
   PubMed Web of Science ®Google Scholar
• Roy P, Tretyakov O, Wright J, Waxman DJ. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metabolism and Disposition 1999; 27: 1309–1318
   PubMed Web of Science ®Google Scholar
• Tamai I, Ling HY, Timbul SM, Nishikido J, Tsuji A. Stereospecific absorption and degradation of cephalexin. Journal of Pharmacy and Pharmacology 1988; 40: 320–324
   PubMedGoogle Scholar
• Wainer IW, Ducharme J, Granville CP. The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemotherapy and Pharmacology 1996; 37: 332–336
   PubMed Web of Science ®Google Scholar
• Wainer IW, Ducharme J, Granvil CP, Trudean M, Leyland-Jones B. Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 1994b; 343: 982–983
   PubMed Web of Science ®Google Scholar
• Wainer IW, Granvil CP, Wang T, Batist G. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Research 1994a; 54: 4393–4397
   PubMed Web of Science ®Google Scholar
• Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemistry and Pharmacology 1994; 47: 1157–1163
   PubMed Web of Science ®Google Scholar
• Wang JH, Chan KK. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. Journal of Mass Spectrometry 1995a; 30: 675–683
   Web of Science ®Google Scholar
• Wang JJ, Chan KK. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and iphosphoramide mustard in plasma by gas chromatographic-mass spectrometry. Journal of Chromatography B 1995b; 674: 205–217
   PubMed Web of Science ®Google Scholar
• Wang JJ, Chan KK. Stereospecific synthesis of tetradeuterated (R)- and (S)-ifosfamide. Journal of Labelled Compounds 1996; 38: 105–115
   Google Scholar
• Wang JJ, Lu H, Chan KK. Stereoselective pharmacokinetics of ifosfamide in male and female rats. AAPS Pharmscience 2000; 2: 1–11
   Google Scholar
• Weber GF, Waxman DJ. Activation of the anti-cancer drug ifosfamide by rat liver microsomal P450 enzymes. Biochemistry and Pharmacology 1993; 45: 1685–1694
   PubMed Web of Science ®Google Scholar
• Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism, Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochrome P450. Drug Metabolism and Disposition 1996; 24: 1254–1262
   PubMed Web of Science ®Google Scholar
• Zheng JJ, Chan KK, Muggia F. Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemotherapy and Pharmacology 1994; 33: 391–398
   PubMed Web of Science ®Google Scholar